Ronald A. DeLellis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ronald A. DeLellis has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Arthur S. Tischler
Department of Pathology, Tufts Medical Center, Tufts University School of Medicine, Boston, USA
3 shared publications Peter Mazzaglia
From the Departments of Pathology (Drs DeLellis and Mangray) and Surgery (Dr Mazzaglia), Rhode Island Hospital and the Miriam Hospital and the Warren Alpert Medical School of Brown University, Providence, RI
2 shared publications- Ronald Ghossein
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
2 shared publications - Shamlal Mangray
Department of Pathology, Rhode Island Hospital and the Alpert Medical School of Brown University, Providence, Rhode Island
2 shared publications - Stephen P. Naber
Memorial Sloane Kettering Cancer Center
2 shared publications A. John Kuta
Radiology Associates of Richmond, Henrico Doctors’ Hospital–Forest
1 shared publication
Latest Publications
- Open Access
- 18 November 2023
- Published by Springer Nature in Endocrine Pathology
- Vol. 34 (4) , 487
Endocrine Pathology Society Hubert Wolfe Award for 2023: Call for Nominations
- 18 November 2023
- Published by Springer Nature in Endocrine Pathology
- Vol. 34 (4) , 487
Open AccessEndocrine Pathology Society Hubert Wolfe Award for 2023: Call for Nominations
- Open Access
- 24 October 2018
- Published by Springer Nature in Endocrine Pathology
- Vol. 29 (4) , 301
Endocrine Pathology Society Hubert Wolfe Award for 2018: Call for Nominations
- 24 October 2018
- Published by Springer Nature in Endocrine Pathology
- Vol. 29 (4) , 301
Open AccessEndocrine Pathology Society Hubert Wolfe Award for 2018: Call for Nominations
- 1 August 2018
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 142 (8) , 998-1005
Plasma Cell Granuloma of the Thyroid: Review of an Uncommon Entity
Plasma cell granuloma (PCG) is characterized by proliferation of polyclonal plasma cells with associated fibrosis and is often considered part of the heterogeneous group of inflammatory myofibroblastic tumors (IMTs). The thyroid is rarely affected by PCG. A patient having PCG associated with Hashimoto thyroiditis (HT) prompted our literature search that revealed 18 cases of PCG, 55% (n = 10) of which occurred together with HT. The etiopathogenesis of PCG is unknown and there is no specific treatment except surgical excision for compressive symptoms. This entity has an excellent prognosis with no evidence of recurrence or metastasis. Lesions of the thyroid with infiltrating plasma cells include HT, fibrous variant of HT, plasmacytoma, plasma cell myeloma, Riedel thyroiditis, IgG4 (immunoglobulin G4)-related disease, IMT, and PCG. Inflammatory myofibroblastic tumor has ALK gene rearrangements and is considered a neoplasm as opposed to PCG, which is a reactive polyclonal plasma cell proliferation. We believe IMT and PCG are distinct entities and consensus definitions are required for avoiding confusion in the literature.
- 1 August 2018
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 142 (8) , 998-1005
Plasma Cell Granuloma of the Thyroid: Review of an Uncommon Entity
Plasma cell granuloma (PCG) is characterized by proliferation of polyclonal plasma cells with associated fibrosis and is often considered part of the heterogeneous group of inflammatory myofibroblastic tumors (IMTs). The thyroid is rarely affected by PCG. A patient having PCG associated with Hashimoto thyroiditis (HT) prompted our literature search that revealed 18 cases of PCG, 55% (n = 10) of which occurred together with HT. The etiopathogenesis of PCG is unknown and there is no specific treatment except surgical excision for compressive symptoms. This entity has an excellent prognosis with no evidence of recurrence or metastasis. Lesions of the thyroid with infiltrating plasma cells include HT, fibrous variant of HT, plasmacytoma, plasma cell myeloma, Riedel thyroiditis, IgG4 (immunoglobulin G4)-related disease, IMT, and PCG. Inflammatory myofibroblastic tumor has ALK gene rearrangements and is considered a neoplasm as opposed to PCG, which is a reactive polyclonal plasma cell proliferation. We believe IMT and PCG are distinct entities and consensus definitions are required for avoiding confusion in the literature.
- 14 December 2017
- Published by Wiley in Histopathology
- Vol. 72 (1) , 117-132
Heritable forms of primary hyperparathyroidism: a current perspective
Primary hyperparathyroidism (PHPT) is one of the most common of all endocrine disorders encountered by the practising histopathologist. The vast majority of lesions are sporadic in nature, approximately 85% of which are parathyroid adenomas, while hyperplasia and carcinoma account for 10–15% and fewer than 1%, of cases, respectively. Heritable forms of PHPT are much less common and present challenges both to clinicians and pathologists, particularly when they are the presenting feature of an endocrine syndrome. In such instances, pathologists play a key role in alerting physicians to the possibility of an underlying heritable endocrine syndrome and the potential for extra‐endocrine manifestations. Therefore, a working knowledge of these disorders is essential for providing guidance to treating physicians. The aim of this update is to review the clinicopathological features, genetic bases and current management for patients with PHPT associated with multiple endocrine neoplasia (MEN) types 1, 2A and 4 and hyperparathyroidism‐jaw tumour (HPT‐JT) syndrome in the context of the 2017 World Health Organization (WHO) Classification of Tumours of the Endocrine Organs. Additionally, familial isolated hyperparathyroidism, familial hypocalciuric hypercalcaemia and neonatal severe hyperparathyroidism are discussed.
- 14 December 2017
- Published by Wiley in Histopathology
- Vol. 72 (1) , 117-132
Heritable forms of primary hyperparathyroidism: a current perspective
Primary hyperparathyroidism (PHPT) is one of the most common of all endocrine disorders encountered by the practising histopathologist. The vast majority of lesions are sporadic in nature, approximately 85% of which are parathyroid adenomas, while hyperplasia and carcinoma account for 10–15% and fewer than 1%, of cases, respectively. Heritable forms of PHPT are much less common and present challenges both to clinicians and pathologists, particularly when they are the presenting feature of an endocrine syndrome. In such instances, pathologists play a key role in alerting physicians to the possibility of an underlying heritable endocrine syndrome and the potential for extra‐endocrine manifestations. Therefore, a working knowledge of these disorders is essential for providing guidance to treating physicians. The aim of this update is to review the clinicopathological features, genetic bases and current management for patients with PHPT associated with multiple endocrine neoplasia (MEN) types 1, 2A and 4 and hyperparathyroidism‐jaw tumour (HPT‐JT) syndrome in the context of the 2017 World Health Organization (WHO) Classification of Tumours of the Endocrine Organs. Additionally, familial isolated hyperparathyroidism, familial hypocalciuric hypercalcaemia and neonatal severe hyperparathyroidism are discussed.
- 1 July 2017
- Published by Wolters Kluwer Health in AJSP: Reviews and Reports
- Vol. 22 (4) , 196-208
Medullary Thyroid Carcinoma
Medullary thyroid carcinoma (MTC) is a thyroid neoplasm with evidence of C-cell differentiation that accounts for approximately 2% to 3% of all thyroid malignancies. Approximately 70% of MTCs are sporadic, whereas the remainder are heritable and occur as a component of the multiple endocrine neoplasia type 2 syndromes. Multifocal primary C-cell hyperplasia is the precursor of the familial cases. In the past several decades, there have been remarkable advances in the understanding of this tumor type and its precursor lesions at the clinical, histopathologic, and molecular genetic levels. This article presents an update on MTC and C-cell hyperplasia in the context of the 2017 World Health Organization Classification of Endocrine Tumors.
- 1 July 2017
- Published by Wolters Kluwer Health in AJSP: Reviews and Reports
- Vol. 22 (4) , 196-208
Medullary Thyroid Carcinoma
Medullary thyroid carcinoma (MTC) is a thyroid neoplasm with evidence of C-cell differentiation that accounts for approximately 2% to 3% of all thyroid malignancies. Approximately 70% of MTCs are sporadic, whereas the remainder are heritable and occur as a component of the multiple endocrine neoplasia type 2 syndromes. Multifocal primary C-cell hyperplasia is the precursor of the familial cases. In the past several decades, there have been remarkable advances in the understanding of this tumor type and its precursor lesions at the clinical, histopathologic, and molecular genetic levels. This article presents an update on MTC and C-cell hyperplasia in the context of the 2017 World Health Organization Classification of Endocrine Tumors.
- 1 December 2013
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 21 (6) , 577-578
Spindle Cell Foci of the Thyroid-Mimicking Malignancy
- 1 December 2013
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 21 (6) , 577-578
Spindle Cell Foci of the Thyroid-Mimicking Malignancy
- 21 November 2013
- Published by Springer Nature in Endocrine Pathology
- Vol. 25 (1) , 3-5
A Brief History of the Endocrine Pathology Society
- 21 November 2013
- Published by Springer Nature in Endocrine Pathology
- Vol. 25 (1) , 3-5
A Brief History of the Endocrine Pathology Society
- 27 November 2012
- Published by Springer Nature
- p. 571-600
Endocrine Pathology
- 17 November 2011
- Published by Springer Nature in Endocrine Pathology
- Vol. 22 (4) , 175
Call for Nominations Endocrine Pathology Society Hubert J. Wolfe Award
- 17 November 2011
- Published by Springer Nature in Endocrine Pathology
- Vol. 22 (4) , 175
Call for Nominations Endocrine Pathology Society Hubert J. Wolfe Award
- Open Access
- 1 August 2011
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 301 (2) , C413-C420
Role of Rac1 in regulation of NOX5-S function in Barrett's esophageal adenocarcinoma cells
We have shown that a novel NADPH oxidase isoform, NOX5-S, is the major isoform of NADPH oxidases in an esophageal adenocarcinoma (EA) cell line, FLO, and is overexpressed in Barrett's mucosa with high-grade dysplasia. NOX5-S is responsible for acid-induced reactive oxygen species production. In this study, we found that mRNA levels of NOX5-S were significantly higher in FLO EA cells than in the normal human esophageal squamous cell line HET-1A or in a Barrett cell line, BAR-T. The mRNA levels of NOX5-S were also significantly increased in EA tissues. The data suggest that NOX5-S may be important in the development of EA. Mechanisms of functional regulation of NOX5-S are not fully understood. We show that small G protein Rac1 was present in HET-1A cells, BAR-T cells, and EA cell lines FLO and OE33. Rac1 protein levels were significantly higher in FLO and OE33 cells than in HET-1A or BAR-T cells. Knockdown of Rac1 with Rac1 small interfering RNA significantly decreased acid-induced increase in H2O2 production in FLO EA cells. Overexpression of constitutively active Rac1 significantly increased H2O2 production, an increase that was blocked by knockdown of NOX5-S. By immunofluorescence staining and immunoprecipitation, we found that NOX5-S was present in the cytosol of FLO EA cells and colocalized with Rac1 and SERCA1/2 Ca2+-ATPase which is located in the endoplasmic reticulum membrane. We conclude that Rac1 may be important in activation of NOX5-S in FLO EA cells.
- 1 August 2011
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 301 (2) , C413-C420
Open AccessRole of Rac1 in regulation of NOX5-S function in Barrett's esophageal adenocarcinoma cells
We have shown that a novel NADPH oxidase isoform, NOX5-S, is the major isoform of NADPH oxidases in an esophageal adenocarcinoma (EA) cell line, FLO, and is overexpressed in Barrett's mucosa with high-grade dysplasia. NOX5-S is responsible for acid-induced reactive oxygen species production. In this study, we found that mRNA levels of NOX5-S were significantly higher in FLO EA cells than in the normal human esophageal squamous cell line HET-1A or in a Barrett cell line, BAR-T. The mRNA levels of NOX5-S were also significantly increased in EA tissues. The data suggest that NOX5-S may be important in the development of EA. Mechanisms of functional regulation of NOX5-S are not fully understood. We show that small G protein Rac1 was present in HET-1A cells, BAR-T cells, and EA cell lines FLO and OE33. Rac1 protein levels were significantly higher in FLO and OE33 cells than in HET-1A or BAR-T cells. Knockdown of Rac1 with Rac1 small interfering RNA significantly decreased acid-induced increase in H2O2 production in FLO EA cells. Overexpression of constitutively active Rac1 significantly increased H2O2 production, an increase that was blocked by knockdown of NOX5-S. By immunofluorescence staining and immunoprecipitation, we found that NOX5-S was present in the cytosol of FLO EA cells and colocalized with Rac1 and SERCA1/2 Ca2+-ATPase which is located in the endoplasmic reticulum membrane. We conclude that Rac1 may be important in activation of NOX5-S in FLO EA cells.